Landscape Capital Management L.L.C. Makes New $4.06 Million Investment in Insmed, Inc. $INSM

Landscape Capital Management L.L.C. purchased a new position in Insmed, Inc. (NASDAQ:INSM) in the third quarter, HoldingsChannel reports. The firm purchased 28,194 shares of the biopharmaceutical company’s stock, valued at approximately $4,060,000.

A number of other hedge funds have also made changes to their positions in INSM. Kingsview Wealth Management LLC raised its holdings in Insmed by 2.7% during the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 60 shares in the last quarter. Choreo LLC increased its position in shares of Insmed by 2.9% during the 3rd quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after purchasing an additional 65 shares during the period. Spire Wealth Management increased its position in shares of Insmed by 11.5% during the 3rd quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 80 shares during the period. MassMutual Private Wealth & Trust FSB raised its stake in shares of Insmed by 59.6% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 81 shares in the last quarter. Finally, Moody Aldrich Partners LLC lifted its holdings in shares of Insmed by 2.4% in the third quarter. Moody Aldrich Partners LLC now owns 5,551 shares of the biopharmaceutical company’s stock valued at $799,000 after buying an additional 132 shares during the period.

Insider Activity at Insmed

In related news, CEO William Lewis sold 10,699 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $146.03, for a total transaction of $1,562,374.97. Following the completion of the sale, the chief executive officer directly owned 301,185 shares in the company, valued at approximately $43,982,045.55. This trade represents a 3.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sara Bonstein sold 748 shares of Insmed stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $156.34, for a total value of $116,942.32. Following the sale, the chief financial officer directly owned 79,758 shares of the company’s stock, valued at approximately $12,469,365.72. The trade was a 0.93% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 189,651 shares of company stock worth $31,784,545. Corporate insiders own 3.00% of the company’s stock.

Insmed Stock Down 0.1%

Insmed stock traded down $0.19 during mid-day trading on Friday, hitting $139.34. The company’s stock had a trading volume of 203,254 shares, compared to its average volume of 2,425,995. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $212.75. The company has a market cap of $30.03 billion, a PE ratio of -21.73 and a beta of 1.13. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. The firm’s 50 day moving average is $155.93 and its 200 day moving average is $165.62.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The business had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. Insmed’s revenue for the quarter was up 152.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.32) EPS. On average, analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on INSM shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research report on Thursday, January 22nd. Rothschild & Co Redburn set a $263.00 target price on shares of Insmed in a report on Thursday, December 4th. Stifel Nicolaus set a $205.00 target price on shares of Insmed in a research note on Thursday, February 19th. Truist Financial set a $205.00 target price on shares of Insmed in a report on Monday, January 12th. Finally, Cantor Fitzgerald lifted their price target on shares of Insmed from $216.00 to $230.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $207.52.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.